An observational study in HIV Infections, sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.
Sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.
Among the 278 studies in HIV Infections with a site in France, this one is the 43rd largest by enrollment of the 59 observational ones that give a count, is one of 9 that started in 2023, is one of 59 observational ones, and was the 261st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
ViiV Healthcare · Sites in France, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in France, Belgium, Germany and 7 more countries
Ages 18+ · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 72 · Phase 3 94 · Phase 4 18
First in 1999; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is below the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 186 across the 213 interventional studies, 200 across the 59 observational. Of the 232 that completed or were terminated, 70 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
111 of 278 have an industry lead sponsor. The 10 most frequent:
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida is the lead sponsor of 20 studies on the registry; 6 are open to participants now.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida has 8 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in HIV Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03296202University Hospital, BordeauxRisk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV | 2026-12 |
| NCT06441123University Hospital, MontpellierDevelopment of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein | 2027-02-10 |
| NCT07552038Nantes University HospitalDental Management of Patients With HIV in Pays de la Loire | 2027-05-30 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 278 studies in HIV Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the SWEED study is to determine whether doravirine containing ART is able to maintain viral suppression at W48 in HIV-1 infected people living with HIV (PLWH) receiving etravirine containing ART:
The evolution of HIV infection from fatal to chronic has been enabled by advances in development and access of antiretroviral treatment (ART), which has also resulted in life expectancy of PLWH approaching that of those uninfected.In addition, over the past few years, new drugs and news regimens have offered improved efficacy, safety and tolerability. The 95-95-95 UNAIDS target, i.e. to diagnose 95% of PLWHIV (1st 95), provide ART to 95% of those diagnosed with HIV (2nd 95), and to reach viral suppression in 95% of patients on ART (3rd 95), is being achieved in several countries. Calls to add a fourth target, i.e. to improve the quality of life for PLWHIV, have grown stronger since the concept was introduced in 2016. The twin aims are long-term treatment durability and improved quality of life with a focus on personalized treatment.
Switching or simplifying ART in the setting of HIV suppression may improve pill burden, dosing frequency, safety, tolerability, and/or food requirements. At times, ART switch or simplification is elective, such as consolidating a multiple-tablet to a single-tablet regimen (STR). Other times, it is necessary to eliminate drug-drug interactions (DDIs) and/or minimize active or potential treatment-associated adverse events (AEs). The fundamental principle of switching or simplifying ART is to preserve virologic suppression without jeopardizing future ART options.
Etravirine, a second generation NNRTI, has been demonstrated to be effective on HIV strains with prior resistance mutations on reverse transcriptase impacting other NNRTIs, such as nevirapine, efavirenz or rilpivirine. It has even been used in salvage therapy, in association with darunavir and raltegravir, in uncontrolled patients with multiresistant strains. Etravirine is mostly prescribed twice daily, and is a strong enzymatic inducer providing many DDIs, complicating its use.
Doravirine, a last generation NNRTI, is approved in treatment-naïve and experienced HIV-infected individuals. In the DRIVE-FORWARD study, doravirine 100 mg QD, in combination with either TDF/FTC or ABC/3TC, achieved high virologic success at week 48 and was non-inferior to DRV/r + 2 NRTIs regardless of baseline HIV-RNA. In the DRIVE-AHEAD study, in treatment-naïve adults with HIV-1 infection, doravirine + 3TC/TDF administered once daily demonstrated a high antiviral potency with non-inferior efficacy to EFV/FTC/TDF regardless of baseline HIV-RNA, and a low rate of resistance, with only 1.6% of participants developing resistance to any study drug through W48. For virologically suppressed patients considering a change in therapy, switching to DOR/3TC/TDF was shown to be a well-tolerated option which was non-inferior to continuation of the previous regimen, with high rates of virologic suppression and low rates of virologic rebound. Long term results from the DRIVE-SHIFT trial showed that doravirine maintained virologic suppression and was generally well tolerated through 144 weeks of treatment. DOR/3TC/TDF as switch therapy showed a favorable lipid profile compared with previous regimens and results in minimal weight gain. The convenience achieved through switching to a DOR based regimen serves to achieve regimen simplification and could respond to patient demands for increased tolerability.
The DOR resistance profile is distinct from that of other NNRTIs with the in vitro selection of mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230, 234 and 236. In vitro studies have also suggested that DOR has activity against viruses with certain mutations selected by other NNRTIs, including the K103N and Y181C mutations. In the DRIVE-SHIFT trial, conducted in virologically suppressed patients, 24 participants had a virus with baseline NNRTI mutations (K103N, Y181C and G190A) and 23/24 who switched to DOR/3TC/TDF remained virologically suppressed at the 48-week follow-up. This suggests that the most frequent NNRTI mutations at RT mutation positions 103, 181 and 190 probably not impact DOR activity in vivo.
Due to its virological properties, we believe that doravirine can advantageously replace etravirine, maintaining control of viral replication, in combination with other antiretrovirals, in virologically controlled patients, despite possible exposure to NNRTIs in the pass. Furthermore, doravirine is taken as a single tablet once a day, and causes almost no drug interactions, unlike etravirine.
This observational, non-interventional, multicenter study will assess the efficacy of switching etravirine to doravirine in virally suppressed PLWH on stable etravirine containing ART, with at least 48 weeks of follow-up
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Who gave their non-opposition for the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
switch from etravirine to doravirine, with no change in associated antiretroviral drugs, will be assessed retrospectively
Measure the virological efficacy at week 48 a doravirine-containing ART to assess the effectiveness of the switch to maintain the virological success to W48
Measure of plasma viral load assessed by RNA quantification using COBAS 6800 system (Roche)
Time frame: 12 months
Ran from Dec 2023 to primary completion in May 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida